whole genome microarray 4 × 44k v2 probe set (Agilent technologies)
Agilent technologies is a verified supplier 
Agilent technologies manufactures this product 
90
Structured Review
Agilent technologies
whole genome microarray 4 × 44k v2 probe set
Whole Genome Microarray 4 × 44k V2 Probe Set, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray+probe+sets/pm36672409-85-69-68
Average 90 stars, based on 1 article reviews
Whole Genome Microarray 4 × 44k V2 Probe Set, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microarray+probe+sets/pm36672409-85-69-68
Average 90 stars, based on 1 article reviews
whole genome microarray 4 × 44k v2 probe set - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Microarray:Article Title: Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling. Article Snippet: Array data were extracted using Agilent Feature Extraction Software (version 10.7) and imported into Rosetta Resolver software (version 7.2.2) for analysis. .. Following background correction and normalization of microarray data, a difference set of significant mRNA expression changes between the parental and resistant cell lines was derived (defined as >1.17-fold and p < 1.00 × 10−4; 11,523 probe IDs) and a subset of 7688 genes that were significantly modulated 1.5-fold or greater (Table S1) were uploaded for Ingenuity Pathway Analysis (IPA) core analysis with either User Data Set or the Agilent Expressing:Article Title: Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling. Article Snippet: Array data were extracted using Agilent Feature Extraction Software (version 10.7) and imported into Rosetta Resolver software (version 7.2.2) for analysis. .. Following background correction and normalization of microarray data, a difference set of significant mRNA expression changes between the parental and resistant cell lines was derived (defined as >1.17-fold and p < 1.00 × 10−4; 11,523 probe IDs) and a subset of 7688 genes that were significantly modulated 1.5-fold or greater (Table S1) were uploaded for Ingenuity Pathway Analysis (IPA) core analysis with either User Data Set or the Agilent Derivative Assay:Article Title: Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling. Article Snippet: Array data were extracted using Agilent Feature Extraction Software (version 10.7) and imported into Rosetta Resolver software (version 7.2.2) for analysis. .. Following background correction and normalization of microarray data, a difference set of significant mRNA expression changes between the parental and resistant cell lines was derived (defined as >1.17-fold and p < 1.00 × 10−4; 11,523 probe IDs) and a subset of 7688 genes that were significantly modulated 1.5-fold or greater (Table S1) were uploaded for Ingenuity Pathway Analysis (IPA) core analysis with either User Data Set or the Agilent Indirect Immunoperoxidase Assay:Article Title: Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling. Article Snippet: Array data were extracted using Agilent Feature Extraction Software (version 10.7) and imported into Rosetta Resolver software (version 7.2.2) for analysis. .. Following background correction and normalization of microarray data, a difference set of significant mRNA expression changes between the parental and resistant cell lines was derived (defined as >1.17-fold and p < 1.00 × 10−4; 11,523 probe IDs) and a subset of 7688 genes that were significantly modulated 1.5-fold or greater (Table S1) were uploaded for Ingenuity Pathway Analysis (IPA) core analysis with either User Data Set or the Agilent |